Company news
bioAffinity Technologies, Inc. news in 2024
bioAffinity Technologies, Inc.'s news releases, calls and decks from 2024, newest first.
bioAffinity Technologies Set for Continued Expansion in 2025
December 11, 2024
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
November 3, 2024
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
October 29, 2024
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
October 20, 2024
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
October 17, 2024
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
October 9, 2024
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
October 8, 2024
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
August 13, 2024
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
August 1, 2024
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
July 8, 2024
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
June 11, 2024
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
May 14, 2024
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
March 31, 2024
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
March 5, 2024
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung
March 4, 2024
bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer
January 22, 2024